HomeCompareACOR vs CL

ACOR vs CL: Dividend Comparison 2026

ACOR yields 302.57% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACOR wins by $92.5K in total portfolio value
10 years
ACOR
ACOR
● Live price
302.57%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$133.5K
Annual income
$200.19
Full ACOR calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — ACOR vs CL

📍 ACOR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACORCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACOR + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACOR pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACOR
Annual income on $10K today (after 15% tax)
$25,718.61/yr
After 10yr DRIP, annual income (after tax)
$170.16/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, CL beats the other by $4,463.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACOR + CL for your $10,000?

ACOR: 50%CL: 50%
100% CL50/50100% ACOR
Portfolio after 10yr
$87.2K
Annual income
$2,825.94/yr
Blended yield
3.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

ACOR
Analyst Ratings
5
Buy
11
Hold
3
Sell
Consensus: Hold
Altman Z
-32.7
Piotroski
3/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACOR buys
0
CL buys
0
No recent congressional trades found for ACOR or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACORCL
Forward yield302.57%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28.6%
Portfolio after 10y$133.5K$41.0K
Annual income after 10y$200.19$5,451.69
Total dividends collected$70.1K$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldHold

Year-by-year: ACOR vs CL ($10,000, DRIP)

YearACOR PortfolioACOR Income/yrCL PortfolioCL Income/yrGap
1← crossover$25,829$15,128.59$11,014$313.84+$14.8KACOR
2$45,896$18,259.36$12,200$415.44+$33.7KACOR
3$64,270$15,161.61$13,607$553.09+$50.7KACOR
4$78,690$9,921.27$15,301$741.41+$63.4KACOR
5$89,875$5,676.30$17,374$1,002.00+$72.5KACOR
6$99,196$3,029.49$19,958$1,367.44+$79.2KACOR
7$107,702$1,562.46$23,243$1,887.87+$84.5KACOR
8$116,034$792.73$27,512$2,642.43+$88.5KACOR
9$124,555$399.09$33,197$3,759.22+$91.4KACOR
10$133,474$200.19$40,973$5,451.69+$92.5KACOR

ACOR vs CL: Complete Analysis 2026

ACORStock

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Full ACOR Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this ACOR vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACOR vs SCHDACOR vs JEPIACOR vs OACOR vs KOACOR vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.